17797-11-4

Usage

Uses

Used in Pharmaceutical Research:
1-(4-Chlorophenyl)-1-methylethylamine is used as a research compound for studying the effects of psychoactive substances on neurotransmitter levels in the brain. Its ability to modulate dopamine, norepinephrine, and serotonin levels makes it a valuable tool in understanding the mechanisms of action of stimulant drugs and their potential therapeutic uses.
Used in Neuroscientific Studies:
In the field of neuroscience, 1-(4-Chlorophenyl)-1-methylethylamine serves as a research chemical to investigate the role of neurotransmitters in various brain functions and disorders. Its psychoactive properties allow researchers to explore the relationship between neurotransmitter levels and cognitive processes, mood regulation, and other neurological phenomena.
Used in Drug Abuse Prevention and Education:
Due to its history of recreational drug use and potential for abuse, 1-(4-Chlorophenyl)-1-methylethylamine is utilized in drug abuse prevention and education programs. By understanding the effects and risks associated with PCA, educators and policymakers can develop strategies to raise awareness about the dangers of substance abuse and promote healthier alternatives.

InChI:InChI=1/C9H12ClN/c1-9(2,11)7-3-5-8(10)6-4-7/h3-6H,11H2,1-2H3

Upstream product

• 623-03-0 4-Cyanochlorobenzene 
• 917-54-4 methyllithium 
• 6258-30-6 2-(4-chlorophenyl)-2-methylpropanoic acid 
• 30568-32-2 2-(4-chlorophenyl)-2-methylpropanenitrile 
• 1000141-65-0 1-(2-azidopropan-2-yl)-4-chlorobenzene 
• 99-91-2 para-chloroacetophenone 
• 1989-25-9 4-chlorocumyl alcohol 
• 94616-84-9 dichloromethylcerium 
• 619-56-7 4-chlorobenzamide 
• 2521-24-6 4-chlorothiobenzamide 
• 64798-38-5 1-chloro-4-(1-isocyanato-1-methylethyl)benzene 
• 2621-46-7 1-chloro-4-isopropylbenzene 

Downstream Products

• 1000141-68-3 C₁₈H₂₂Cl₂N₂O₂S 
• 1217337-03-5 5-(3-(2-(4-chlorophenyl)propan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 66897-74-3 N-allyl-N-(α,α-dimethyl-4-chlorobenzyl)benzenesulfonamide 
• 1357456-29-1 C₂₉H₃₄Cl₂N₄OS 
• 1202700-40-0 N-{[1-[(2-chlorophenyl)methyl]-5-({[1-(4-chlorophenyl)-1-methylethyl]amino}carbonyl)-4,6-dihydroxy-2-oxo-1,2-dihydro-3-pyridinyl]carbonyl}glycine 
• 1227936-69-7 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide 
• 1227946-70-4 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-6-carboxamide 
• 1227945-01-8 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrido[4,3-d]pyrimidine-7-carboxamide 
• 1217347-87-9 4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-chlorophenyl)-N-(2-(4-chlorophenyl)propan-2-yl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide 
• 21317-34-0 2,2'-Di-(p-chlor-phenyl)-<2,2'>azopropan 

Relevant academic research and scientific papers

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent

The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019–0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40–>120 μM) towards Vero cells. Significant improvements in mouse liver microsomal stability and mouse pharmacokinetic profile were realized by introduction of an α α-dimethylbenzyl moiety. Among these compounds, JSF-4088 is highlighted due to its in vitro antitubercular potency (MIC = 0.019 μM) and Vero cell cytotoxicity (CC50 > 120 μM). The findings suggest a rationale for the continued evolution of this promising series of antitubercular small molecules.

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-pyrrolo[1,2-a]pyrimidine-8-carboxarnide compounds and variants thereof.

PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.

C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS

The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.

SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[l,5-a]pyrimidine compounds described herein include 5,7- dimethyl-N-phenylpyrazolo[l,5-a]pyrimidine-3-carboxamide compounds and variants thereof.

NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

Evidence for significant through-space and through-bond electronic coupling in the 1,4-diphenylcyclohexane-1,4-diyl radical cation gained by absorption spectroscopy and DFT calculations

Photoinduced single-electron-transfer promoted oxidation of 2,5-diphenyl-l,5-hexadiene by using N-methylquinolinium tetrafluoroborate/ biphenyl co-sensitization takes place with the formation of an intense electronic absorption band at 476 nm, which is attributed to the 1,4-diphenylcyclohexane-1,4-diyl radical cation. The absorption maximum (λob) of this transient occurs at a longer wavelength than is expected for either the cumyl radical or the cumyl cation components. Substitution at the para positions of the phenyl groups in this radical cation by CH3O, CH3, F, Cl, and Br leads to an increasingly larger redshift of λob. A comparison of the ρ value, which was obtained from a Hammett plot of the electronic transition energies of the radical cations versus σ+, with that for the cumyl cation shows that the substituent effects on the transition energies for the 1,4-diarylcyclohexane-1,4-diyl radical cations are approximately one half of the substituent effects on the transition energies of the cumyl cation. The observed substitu_ent-induced redshifts of λob and the reduced sensitivity of λob to substituent changes are in accordance with the proposal that significant through-space and -bond electronic interactions exist between the cumyl radical and the cumyl cation moieties of the 1,4-diphenylcyclohexane-1,4-diyl radical cation. This proposal gains strong support from the results of density functional theory (DFT) calculations. Moreover, the results of time-dependent DFT calculations indicate that the absorption band at 476 nm for the 1,4-diphenylcyclohexane-1,4-diyl radical cation corresponds to a SOMO-3-SOMO transition.

Organocerium reactions of benzamides and thiobenzamides: A direct synthesis of tertiary carbinamines

A simple and efficient process has been developed for the direct conversion of benzamides and thiobenzamides into tertiary carbinamines. A synthesis of benzonitriles from simple benzamides and a thiobenzamide is also described.

Synthesis and Herbicidal Activities of 1,2-Benzisoxazole-3-acetamide Derivatives

Many 1,2-benzisoxazole-3-acetamides were synthesized and their herbicidal activities in the paddy field were studied.Of the compounds tested, N-α,α-dimethylbenzyl-2-bromo-(1,2-benzisoxazol-3-yl)acetamide 10a was the most effective.Details of the synthesis and the results of herbicidal evaluations are given.